Vididencel

Press release Stockholm, Sweden, June 17, 2024 ALL PATIENTS WITH CONFIRMED TUMOR ANTIGEN-SPECIFIC T CELL REPONSES FOLLOWING VIDIDENCEL TREATMENT REMAIN ALIVE IN LONG-TERM FOLLOW-UP Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it has presented data from the ADVANCE II phase 2 trial with its lead product vididencel in acute myeloid leukemia (AML) during the annual European Hematology Association conference (EHA). The data confirm the potential of vididencel to stimulate functional immune responses in AML patients, comprising T cell and B cells. All patients with confirmed T cell responses against tumor antigens following vididencel treatment were alive in long-term follow-up at the time of read-out. AML is an aggressive blood-borne tumor which is characterized by a high relapse rate and low overall survival. The ADVANCE II Phase 2 trial focuses on AML patients in first complete remission following intensive induction chemotherapy, who are diagnosed with measurable residual disease (MRD), which is associated with an increased relapse risk. At a median follow-up for the total study population of 31.6 months, the majority of patients (14/20) were alive and relapse-free survival stood at 30.4 months. Immune responses against at least one tumor antigen were observed in the majority of patients following vididencel treatment. The data presented at EHA specifically addressed which type of immune responses were most strongly associated with survival outcomes. The data showed significantly better survival in patients with a confirmed tumor antigen-specific T cell response, versus patients without such a confirmed T cell response. All of the patients with a confirmed T cell response remained alive in long-term follow-up at the time of read-out. Durable clinical remissions were also associated with increased levels of circulating B cells. The data indicate that functional immune responses following vididencel treatment involve both T cells and B cells and that the breadth of the immune response contributes to long-term disease control and survival in AML.“The data presented at EHA deepen our understanding of vididencel as an immunotherapy for AML patients in need of maintenance treatment to prevent or delay disease relapse,” said Jeroen Rovers, CMO of Mendus. “The observation that functional immune responses occur in AML patients following vididencel treatment, despite the nature of the disease and preceding treatment with intensive induction chemotherapy, is encouraging. The date strongly supports the use of vididencel as a maintenance immunotherapy for AML, based on long-term survival benefit related to active immunity against residual disease.” Please see below for abstract details: Abstract Number: P1437 (poster presentation) Abstract Title: Long term survival in AML patients after immunotherapy with vididencel correlates with functional T and B-cell responses Authors: Arjan van de Loosdrecht, Hester van Zeeburg, Jeroen Rovers, Jacqueline Cloos, Eva Wagner-Drouet, Uwe Platzbecker, Tobias Holderried, Catharina van Elssen, Aristoteles Giagounidis, Bjørn T. Gjertsen Session Date & Time: Friday, 14 June 2024 between 18:00 – 19:00 CEST Peripheral blood samples were collected at baseline and different time points up to 32 weeks following start of vididencel treatment. IFNg ELISPOT assays were used to detect functional T cell responses against well-documented AML antigens (WT-1, RHAMM and PRAME).The majority of patients (17/20) showed at least one vaccine-induced T-cell response. A significantly better overall survival (OS) was observed in patients with two or more T-cell responses at different time points toward at least one of the antigens tested (confirmed T cell response), versus patients without such a confirmed response (p = 0.005, log rank statistical test between groups). In addition, detailed analysis using multiparametric flow cytometry was performed, to distinguish > 100 immune cell subsets for each patient at each timepoint. Distinct differences were observed between patients with durable clinical remissions and patients who relapsed. Overall survival was associated with increased B-cell levels, suggesting an important role for vididencel-induced B-cell responses in the control of residual disease. The data substantiate a link between the use of vididencel and the potential to induce a functional T cell and B cell-mediated immune response, leading to long-term survival in AML.The poster presented at EHA can be viewed on the Mendus website.

Press Release Stockholm, Sweden, March 15, 2024 Mendus AB (“Mendus” or the “Company”) has received written declarations of intent whereby the Company’s major shareholders, holding approximately 65.8 percent of shares in the Company, declare their intention to exercise warrants of series TO3 (the “Warrants”) to subscribe for newly issued shares corresponding to their holdings of Warrants during the subscription period 15-29 March 2024 at the subscription price of 0.48 SEK per share. The major shareholders have confirmed that their holdings of Warrants at least equal the number that was allotted to them in connection to their participation in the rights issue in July 2023. All shareholding members of the Company’s Board of Directors and Management team have also declared their intention to exercise all their Warrant holdings. In total, these declarations of intent are expected to result in the exercise of approximately 71.6 percent of the outstanding Warrants. Mendus’ CEO Erik Manting comments: “The commitments by our largest shareholders, together with all the shareholding members of the board and all in the management team, to exercise their warrants which were issued during our latest financing round in July 2023 underscores the progress made by Mendus since. After the positive Phase 2 data presented at the ASH2023 conference in December, we were happy to present the major steps we are taking to expand the clinical development and to scale-up the manufacturing of vididencel together with our partners ALLG and NorthX Biologics at our Business Update event earlier this week. We are also very grateful for the continued support by our shareholders.” The outstanding Warrants were allotted as part of the units that were subscribed for in connection to the preferential rights issue and the directed issue that Mendus carried out in July 2023. If all outstanding Warrants are exercised, the Company will receive approximately SEK 90.6 million in gross proceeds. The declarations of intent are expected to lead to the exercise of approximately 71.6 percent of the outstanding Warrants. The declarations of intent have been made by Van Herk Investments BV, Flerie Invest AB (publ) and Fjärde AP-fonden as well as all shareholding members of the Board of Directors and Management team. The declaration of intent from Van Herk Investments BV is contingent upon them receiving an exemption from the Securities Council (Sv. “Aktiemarknadsnämnden”) to be able to increase their shareholding. In the event that such exemption is not received, Van Herk Investments BV will exercise warrants such that, following the outcome of the exercise period, their percentage ownership will remain unchanged. The declaration of intent from Fjärde AP-fonden to exercise their Warrant holdings is conditional upon their shareholding in the Company not exceeding 9.9 percent. Accordingly, the actual number of Warrants exercised by Van Herk Investments BV and Fjärde AP-fonden will depend on the aforementioned conditions. FOR MORE INFORMATION, PLEASE CONTACT: Erik MantingChief Executive OfficerE-mail: ir@mendus.com ABOUT MENDUS AB (PUBL)Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/ Attachment 240315 Mendus - Warrants Commitment ENG